SCHEMBL521727

SCHEMBL521727

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
TDP1 Q9NUW8 2/20 0.65
KDM4E B2RXH2 2/20 0.46
PDE4A P27815 1/20 0.46
USP2 O75604 1/20 0.42
SLCO1B1 Q9Y6L6 1/20 0.42
ALDH1A1 P00352 3/20 0.38
NR1I2 O75469 1/20 0.38
CYP1A2 P05177 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.33
TOP1 P11387 1/20 0.32
MGAM O43451 1/20 0.31
SI P14410 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10620808 1.00 LMNA (0.69) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL5133813 1.00 LMNA (0.69) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL5051917 0.94 LMNA (0.59) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL5028006 0.94 LMNA (0.59) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL5052085 0.94 LMNA (0.59) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL756618 0.94 LMNA (0.59) LMNAL3MBTL1TDP1KDM4EPDE4A
SCHEMBL20239655 0.87 LMNA (0.44) LMNAL3MBTL1TDP1ALDH1A1NR1I2
Mannitol SCHEMBL23066399 0.83 LMNA (1.00) LMNAL3MBTL1TDP1KDM4EPDE4A
Mannitol SCHEMBL2477078 0.83 LMNA (1.00) LMNAL3MBTL1TDP1KDM4EPDE4A
Mannitol SCHEMBL2297640 0.83 LMNA (1.00) LMNAL3MBTL1TDP1KDM4EPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213655-A1 COMPOSITIONS AND METHODS OF USE GENENTECH INC (US) 2025-07-03 US claimed
CN-119950683-A Implantable polymer depot for controlled sustained release of therapeutic agents 铸造疗法股份有限公司 2025-05-09 CN claimed
WO-2025021320-A1 RETINOL CONTAINING DAY CREAM THE BOOTS COMPANY PLC (GB) 2025-01-30 WO claimed
US-11883453-B2 Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation PHYTOPLENUS BIOATIVOS S.A (BR) 2024-01-30 US claimed
EP-4301346-A1 STABLE PHARMACEUTICAL COMPOSITIONS OF METFORMIN ORION CORPORATION (FI) 2024-01-10 EP claimed
CN-116327681-A Gel formulations comprising substituted imidazo [1, 2-alpha ] pyridin-2-ylamine hydrochloride hydrate 上海复旦张江生物医药股份有限公司 2023-06-27 CN claimed
WO-2022184981-A1 STABLE PHARMACEUTICAL COMPOSITIONS OF METFORMIN ORION CORPORATION (FI) 2022-09-09 WO claimed
CN-114652661-A Liquid composition with anti-aging effect and application thereof in cosmetics 启迪禾美生物科技(嘉兴)有限公司 2022-06-24 CN claimed
US-20220183964-A1 IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS FOUNDRY THERAPEUTICS, INC. 2022-06-16 US claimed
EP-3952847-A1 IMPLANTABLE POLYMER DEPOTS FOR THE CONTROLLED, SUSTAINED RELEASE OF THERAPEUTIC AGENTS Foundry Therapeutics, Inc. (US) 2022-02-16 EP claimed
CN-101312953-A Sulfur-containing pharmacologically active compounds JON PTY LTD (AU) 2008-11-26 CN claimed
US-20080132563-A1 1-Thio-D-Glucitol Derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-06-05 US claimed
CN-101103013-A 1-thio-D-glucitol derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 2008-01-09 CN claimed
EP-1845095-A1 1-THIO-D-GLUCITOL DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2007-10-17 EP claimed
CN-1299668-C Nanometer realgar solid dispersion and its preparation method UNIV HUAZHONG SCIENCE TECH (CN) 2007-02-14 CN claimed
CN-1245975-C Medicinal composition for stabilizing delotadine in preparation TIANJIN MEDICINE ACADEMY (CN) 2006-03-22 CN claimed
CN-1552324-A Medicinal composition for stabilizing delotadine in preparation 天津药物研究院 2004-12-08 CN claimed
EP-1304048-B1 Composition to reduce or quit smoking addiction PERA IVO (US) 2004-09-22 EP claimed
CN-1478486-A Nanometer realgar solid dispersion and its preparation method 华中科技大学 2004-03-03 CN claimed
US-4585844-A BASIC COMONOMER E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-04-29 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132563-A1 1-Thio-D-Glucitol Derivatives SLC5A1, SLC5A2, SLC5A11 LMNA 4616/4885L3MBTL1 1990/4885TDP1 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.